Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy
Public ClinicalTrials.gov record NCT00468845. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multiple Dose, Randomized, Double-Blind Multicenter Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo In The Treatment Of Patients With Post-Surgical Pain From Hysterectomy
Study identification
- NCT ID
- NCT00468845
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Enrollment
- 501 participants
Conditions and interventions
Conditions
Interventions
- matched placebo Drug
- pregabalin (Lyrica) Drug
Drug
Eligibility (public fields only)
- Age range
- 25 Years to 70 Years
- Sex
- Female
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2007
- Primary completion
- Apr 30, 2010
- Completion
- Sep 30, 2010
- Last update posted
- Feb 9, 2021
2007 – 2010
United States locations
- U.S. sites
- 14
- U.S. states
- 6
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Mobile | Alabama | 36608 | — |
| Pfizer Investigational Site | Glendale | Arizona | 85308 | — |
| Pfizer Investigational Site | Phoenix | Arizona | 85020 | — |
| Pfizer Investigational Site | Phoenix | Arizona | 85023 | — |
| Pfizer Investigational Site | Phoenix | Arizona | 85027 | — |
| Pfizer Investigational Site | Glendale | California | 91206 | — |
| Pfizer Investigational Site | Pasadena | California | 91105 | — |
| Pfizer Investigational Site | Miami | Florida | 33136-1096 | — |
| Pfizer Investigational Site | Miami | Florida | 33136 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19104 | — |
| Pfizer Investigational Site | Pittsburgh | Pennsylvania | 15213 | — |
| Pfizer Investigational Site | Pittsburgh | Pennsylvania | 15232 | — |
| Pfizer Investigational Site | Houston | Texas | 77024 | — |
| Pfizer Investigational Site | Houston | Texas | 77054 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00468845, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 9, 2021 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00468845 live on ClinicalTrials.gov.